title: Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial.
abstract: BACKGROUND
  Buccal misoprostol 800 mcg and sublingual misoprostol 400 mcg demonstrate high efficacy and few adverse effects when used with 200 mg mifepristone for medical abortion through 63 days since the last menstrual period (LMP). Little is known about a 400-mcg buccal dose. This study compares two in-the-mouth routes of misoprostol using the same dose.
  
  
  METHODS
  Eligible and consenting women (n=550) were randomized to 400 mcg of misoprostol buccally or sublingually 24 h after ingestion of 200 mg of mifepristone. Abortion status was assessed 2 weeks later.
  
  
  RESULTS
  Complete abortion occurred in 97.1% of the buccal group and 97.4% of the sublingual group (p=.97, RR: 1.00, 95% CI=0.97-1.03). Adverse effects were similar in both groups. Over 90% of women in both arms expressed high satisfaction with the method.
  
  
  CONCLUSIONS
  Both 400 mcg buccal misoprostol and 400 mcg sublingual misoprostol after mifepristone appear to be good options for medical abortion through 63 days' LMP.
authors.affiliation: Gynuity Health Projects, New York 10010, USA. sraghavan@gynuity.org
authors.forename: Sheila
authors.initials: S
authors.lastname: Raghavan
authors.forename: Rodica
authors.initials: R
authors.lastname: Comendant
authors.forename: Irena
authors.initials: I
authors.lastname: Digol
authors.forename: Sergiu
authors.initials: S
authors.lastname: Ungureanu
authors.forename: Iurie
authors.initials: I
authors.lastname: Dondiuc
authors.forename: Steliana
authors.initials: S
authors.lastname: Turcanu
authors.forename: Beverly
authors.initials: B
authors.lastname: Winikoff
mesh_terms: D000019:Abortifacient Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced; D000278:Administration, Buccal; D000286:Administration, Sublingual; D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D017060:Patient Satisfaction; D016896:Treatment Outcome
chemical_list: D000019:Abortifacient Agents; D016595:Misoprostol; D015735:Mifepristone